First Cancer Immunotherapy Regimen Approved for Breast Cancer
March 9th 2019Atezolizumab (Tecentriq) plus chemotherapy is approved under the FDA’s Accelerated Approval Program, which allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition.
Read More